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Fibrosis of the liver is a complex and progressive process initiated
and maintained by a large number of stimuli. Signiﬁcant progress
has been made in the past two decades in elucidating the mech-
anism(s) of ﬁbrogenesis and exploring old and new therapeutic
modalities to slow down and possibly reverse ongoing scarring
of the liver [1]. Various strategies to prevent, minimize, and even
revert hepatic ﬁbrosis have been and still are being evaluated in
bile duct ligated (BDL) or CCL4 treated rat model systems as well
as in humans, including removal of the injurious stimuli, sup-
pressing inﬂammation, down-regulating stellate cell activation
and increasing apoptosis of Ito cells. Hepatic stellate cells (HSC)
have emerged as an attractive target for controlling ﬁbrosis. Pro-
liferation of HSC which acquire a myoﬁbroblast phenotype and
synthesize increasing amounts of extracellular matrix is consid-
ered a cornerstone in generation of hepatic ﬁbrosis. Already in
1994, Mallat and co-workers have shown in vitro that simvastatin
inhibits hydroxyl-methylglutaryl-coenzyme A reductase activity
and myoﬁbroblast-like Ito cells, isolated from normal human
liver, independent of its lipid lowering effects [2]. At that time
it was still unknown if this effect also exists in vivo. Since then,
several reports appeared describing the inhibitory effects of stat-
ins on hepatic inﬂammatory activity in vitro [3], portal hyperten-
sion [4], and indirectly on hepatic ﬁbrosis [5]. Statins have also
been reported to have an anti-ﬁbrotic activity in non-hepatic dis-
orders including pulmonary and renal ﬁbrosis [6].
In this issue of the journal, Trebicka and co-workers have eval-
uated in vivo the anti-ﬁbrotic effect of atorvastatin in a BDL rat
model. The investigators employed a broad battery of assays to
evaluate the effects of atorvastatin on HSC activation, prolifera-
tion, and apoptosis as well as degree of hepatic ﬁbrosis. The
BDL rat model is characterized by rapid development of hepatic
ﬁbrosis as assessed by an increased hydroxyproline content as
well as deposition of extracellular matrix. Sham operated rats
served as controls and rats were sacriﬁced at 1, 2, 3, 5, and
6 weeks post BDL. The main results of this study are the attenu-
ation of HSC activation, hepatic ﬁbrosis, and reduced accumula-
tion of myoﬁbroblasts observed in atorvastatin treated rats as
compared to controls, when treatment was started immediately
or early after BDL. In contrast, the anti-ﬁbrotic effects of atorva-
statin were diminished when treatment was started later, at 3–Journal of Hepatology 20
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proﬁbrotic cytokine expression with decreased apoptosis and
proliferation. Interestingly, in contrast to previous reports, treat-
ment had no effect on inﬂammatory activity and hepatocellular
injury even increased. The investigators suggest that it is now
time to test whether the anti-ﬁbrotic effect of atorvastatin
observed in the rat model system is also functional in humans
i.e. with chronic liver disease. However, this is not expected to
be an easy task. The BDL model in the rat is characterized by very
rapid development of ﬁbrosis which is usually present already at
1 week after bile duct ligation. In humans, evolution of ﬁbrosis
may take years or even decades and the option of performing
serial liver biopsies to evaluate the effect of statins is limited,
unless non-invasive markers for ﬁbrosis will be accepted as sur-
rogate end-points. Yet, there is already some indirect evidence
that administration of statins in non-alcoholic liver disease is rel-
atively safe and quite beneﬁcial in reducing the hepatic fat con-
tent which is a well established risk factor for hepatic ﬁbrosis
[7]. In summary, analysis of the results obtained in this rat BDL
model, conﬁrm the original in vitro observation from 1994
regarding the anti-ﬁbrotic properties of statins [2] which were
later also shown to contribute to a reduction in portal hyperten-
sion in humans with cirrhosis [4].Terra Incognita: paving the road for measurement of hepatic
vein pressure gradient in children with chronic liver disease
Measurement of the hepatic vein pressure gradient (HVPG) in
adults is considered a safe and straightforward procedure with a
95% success rate in experienced hands [8]. HVPG has been used
for clinical evaluation of alcoholic liver disease, in patients await-
ing liver resection, in patients with ascites and splenomegaly of
undetermined etiology, in patients with esophageal varices, and
for monitoring of therapy in portal hypertension. An HVPG mea-
surement is also essential prior and after transjugular intrahepatic
portosystemic shunting (TIPS) [9]. Cumulative experience sug-
gests that in adults, bleeding from esophageal varices usually
occurs at anHVPG of at least 12 mmHg. In contrast to adults, there
is very little information on the dynamics of portal pressure in
healthy children as well as in children with chronic liver disease.
In this issue of the journal,Miraglia and co-workers report their
experience in the measurement of HVPG in 20 children, eight
months to 16 years old with a wide spectrum of chronic liver
diseases, of which nine had biliary atresia. HVPG between 1010 vol. 53 j 591–592
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and 33 mm Hg – was found in 13/20 children, nine of whom also
had esophageal varices. In addition, collateral circulation was also
identiﬁed in 3/4 children with an HVPG of 8 mm Hg of whom two
had esophageal varices. In contrast, none of the children with an
HVPG between 2 and 3 mm Hg had collaterals or varices. Based
on their preliminary results, the investigators suggest an HVPG
P8 mmHg should be considered as evidence for portal hyperten-
sion in children. This ﬁgure is lower by 2–4 mm Hg compared to
the acceptable threshold of 10–12 mm Hg in adults. Information
on HVPG levels in healthy children without liver disease is lacking
for obvious reasons. Interestingly, 7/9 children with biliary atresia
had intrahepatic veno-venous shunts which may lead to under-
estimation of the degree of portal hypertension, as observed in
the 3/4 patients with an HVPG of 8 mm Hg. Finally, ten of the
patients with an HVPG between 8 and 20 mm Hg received beta
blocker treatment which was most probably under dosed.
The results of this pilot study suggest that measurement of
HVPG in a pediatric population, which included also very small
children, is safe and may be utilized for the same indications
as in adults. This paper also provides a wealth of technical infor-
mationwhichwill be useful for radiologists and pediatric hepatol-
ogists alike. Finally, the results of this retrospective analysis may
be useful for physicians who consider TIPS, which until recently
was an uncommon procedure in children (reviewed in [10]).Conﬂict of Interest
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